abstract |
(57) Abstract The present invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin α v β 3 receptor, and the genes encoding them. Such antibodies are useful for the therapeutic and / or prophylactic treatment of α v β 3 -mediated disorders, such as restenosis, in human patients. |